CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
(BCMA)-specific chimeric antigen receptor (CAR) and manufactured with a new process. CAR-T cells will be investigated as a single agent in multiple...
Phase 1
Westwood, Kansas, United States and 12 other locations
versus standard regimens in subjects with relapsed and refractory multiple myeloma (RRMM).The study is anticipated to randomize app...
Phase 3
Westwood, Kansas, United States and 59 other locations
progression-free survival (PFS) in participants with newly diagnosed multiple myeloma (a blood cancer of plasma cells) who are not ...
Phase 3
Kansas City, Missouri, United States and 211 other locations
versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in newly diagnosed multiple...
Phase 3
Kansas City, Kansas, United States and 126 other locations
The purpose of this study is to evaluate the effectiveness and safety of BMS-986393 in participants with relapsed or refractory multiple myeloma...
Phase 2
Westwood, Kansas, United States and 41 other locations
(LD-Dex) (Cohort B) in subjects with relapsed or refractory multiple myeloma who have received a first or second line treatment of ...
Phase 2
Kansas City, Missouri, United States and 48 other locations
determine the Recommended Phase 2 Dose and clinical benefit of elranatamab in combination with other anti-cancer therapies in participants with multiple...
Phase 2
Kansas City, Kansas, United States and 38 other locations
monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Pa...
Phase 3
Mission, Kansas, United States and 218 other locations
phase 3 dose (RP3D) in adult participants with newly diagnosed multiple myeloma (NDMM). Participants will receive the combination o...
Phase 1
Westwood, Kansas, United States and 40 other locations
combination with DEX for Relapsed Refractory Multiple Myeloma (RRMM), CC-220 in combination with DEX and BTZ, and CC-220 in combin ...
Phase 1, Phase 2
Fairway, Kansas, United States and 88 other locations
Clinical trials
Research sites
Resources
Legal